Spot on, the primary value would be to bundle up with a statin,...

First 117 Last

Share
Profile

Follow
All4Info

596 Posts.

265

22/02/22

12:50

Post #: 59731104
Share

Originally posted by FreeBobby2002: ↑

Company looks very interesting gang, just started doing some DD after seeing Tony Locantro call this his #1 stock pick for 2022. I had no idea about the prevalence of cholesterol lowering drugs. It's very encouraging that NYR's drug had outperformed Lipitor as a single agent in the same mouse model, with that awesome reduction when used in combination.

I am still early in my research so sorry if this has been discussed before, but would it be possible to patent the combination of Lipitor with NYR's drug to sell this combo as a single agent?

The user experience aspect of delivering this via a pill, versus frequent injections like Praluent, is also very important I think, both from the convenience but also price perspective. There are some medical treatments out there with low rates of continued usage despite efficacy, CPAP machines come to mind

Thanks to all holders and commenters contributing here, greatly helping with my research!

Expand

Spot on, the primary value would be to bundle up with a statin, offer as a single treatment. And yes, should have no probs with patenting that its a new treatment.

Secondary value as a stand alone treatment for those where a statin is ineffective. Could licence out right to use in conjunction with statin, and retain stand alone use development... a few options I suppose.

NYR Price at posting: 20.0¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply